Results from the Six-Month Interim Readout of the Human PK Iluvien™ Study
News Oct 07, 2008
Drug delivery company, pSivida Corp. together with its licensing and development partner, Alimera Sciences have reported the interim six-month safety and efficacy results from the first human pharmacokinetic study of Medidur™ FA, which will be marketed under the trade name Iluvien™, if approved by the U.S. Food and Drug Administration.
This 36 month, open label Phase II study, running concurrently with the pivotal Phase III FAME™ study (Fluocinolone Acetonide in Diabetic Macular Edema), is designed primarily to assess systemic exposure of the corticosteroid, fluocinolone acetonide (FA) after administration of Iluvien in diabetic macular edema (DME) patients.
The study is also designed to provide information on the safety and efficacy of Iluvien in a DME population. A total of 37 subjects were enrolled in the PK study, 20 patients received a low-dose Iluvien and 17 patients received a higher-dose Iluvien.
The six-month interim readout from the PK study showed 25% of the low dose patients and 41% of the higher dose patients had an improvement in best corrected visual acuity (BCVA) of 10 or more letters on an eye chart compared with their baseline vision. In addition, the sixmonth readout showed 18% of the higher dose patients had an improvement in BCVA of 15 or more letters from baseline.
The percentage of low dose patients that had an improvement in BCVA of 15 or more letters from baseline decreased from the 20% seen at the three-month readout due to one patient having developed a cataract and one patient having developed an epiretinal membrane involving the macula prior to the readout. The development of cataracts and epiretinal membranes in a diabetic population are not unusual and are commonly addressed with surgical intervention.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.